Table I.

Clinicopathological features of primary TLFCK reported between 2006 and 2012.

First author/s (ref)	Age, year	Gender	Presentation	Tumor location	Tumor size, cm (location)	TNM stage	Treatment	Disease-free survival
Amin et al (2)	53	Female	Incidental	Right kidney (middle pole)	2.1	pT1aNx	RN	4 years and 6 months
	29	Female	Incidental	Right kidney (upper pole)	1.9	pT1aNx	RN	7 years
	45	Male	Incidental	Right kidney (lower pole)	3.5	pT1aN1	RN	1 year and 5 months
	83	Male	Incidental	Left kidney (lower pole)	2.1	pT1aNx	RN	4 years
	35	Male	Incidental	Right kidney (middle pole)	3.0	pT1aNx	RN	1 year and 8 months
	50	Female	Incidental	Right kidney (middle pole)	4.0	pT1aN0	RN	7 months
Jung et al (1)	32	Female	Incidental	Right kidney (middle and lower poles)	11.8	pT2Nx	RN	6 months
Xu and Zang(3)	36	Female	Hematuria of the middle course of urination with blood clots	Left kidney (middle-lower pole)	10.0	pT2Nx	RN	1 year
He et al (4)	22	Female	Painless hematuria	Left kidney	8.0	pT1aN0	RN	No data
Sterlacci et al (5)	29	Female	Incidental	Left kidney (middle pole)	4.3	/	RN	Left lung lower lobe metastasis at 2 months, disease-free survival for 5 years
Dhillon et al (6)	34	Female	Hematuria and right back pain	Right kidney (middle pole) and bilateral lungs	6.3 (right kidney) 2.1 (left lung) 3.4 (right lung)	pT2N0M1	RN	1 year
Present study	65	Male	Hematuria and right back pain	Right kidney (middle-lower pole)	8.0	pT2N0	RN	15 months
	59	Male	Incidental	Right kidney (middle-lower pole)	5.2	pT1aN0	RN	1 month

RN, radical nephrectomy; TLFCK, thyroid-like follicular carcinoma of the kidney; TNM, tumor-node-metastasis.